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The pharmacology of the two general groups of 
oral anti-diabetic agents, namely the sulfonylureas 
and biguanides, are briefly discussed here. The sul-
fonylureas have a common hypoglycemic core. These 
sulfonylurea compounds can be divided into short, 
intermediate, and long-acting agents, with varying 
half-lives, and duration of action. Therapeutic doses 
of sulfonylureas have produced wide variations in 
serum levels depending upon the rates of absorption, 
rates of metabolism, renal clearance, and degree of 
protein-binding. Tolbutamide is a short-acting agent 
metabolized by the liver to inactive compounds 
which are excreted by the kidney; it has a half-life of 
four to five hours, a duration of action of approxi-
mately six to ten hours, and is given in divided daily 
dosage. Acetohexamide and tolazamide, the inter-
mediate-acting compounds, are metabolized by the 
liver. Approximately 75% of acetohexamide is me-
tabolized to another hypoglycemic compound, and 
tolazamide is metabolized to several hypoglycemic 
products. The duration of the action of these agents is 
approximately 10 to 16 hours; they are administered 
either once or twice daily . Chlorpropamide is only 
slightly altered, less than l % being metabolized, 
probably in the liver; it is firmly bound to protein, is 
dependent on renal excretion for clearance, and, as it 
has a duration of action varying from 35 to 72 hours, 
it is given only once daily. 
Sulfonylurea compounds appear to exert their 
primary action through direct stimulation of pan-
creatic insulin secretion. Peripheral insulin levels cor-
relate with blood sugar levels during acute therapy, 
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but do not appear to correlate with blood sugar-
lowering effect of chronic drug therapy. Hence, im-
portant extra-pancreatic actions may be responsible 
for the hypoglycemic effects of these compounds, that 
is, induced hepatic glycolytic enzymes, impaired in-
sulin sensitivity, increased membrane receptors, 
lowered insulin resistance, or other as yet undefined 
mechanisms. 
Phenformin, a biguanide, is metabolized to some 
extent by the liver, but approximately 65% may be 
excreted unchanged by the kidneys. The hypogly-
cemic effect of the "short-acting" tablet lasts six to 
eight hours. In contrast, the timed disintegration cap-
sule has a duration of action from 8 to 14 hours 
because of prolonged gastrointestinal absorption of 
the drug. The mode of action of these agents is not 
completely understood. There is evidence that phen-
formin lowers blood sugar levels by accelerating ane-
robic glycolysis and delays the absorption of glucose 
from the gastrointestinal tract. Phenformin also de-
creases hepatic gluconeogenesis of diabetic animals, 
but this has not been confirmed in man. It is also 
quite possible that the anorexigenic effects of this 
agent may lower caloric intake, and help exert its 
hypoglycemic action in this manner . 
Side effects and toxic effects are relatively rare 
with the sulfonylureas. Hematologic, hepatic, and 
dermatologic reactions have been described. An "an-
tabuse" effect has been noted with chlorpropamide. 
Rare cases of hypersensitivity angiitis have been de-
scribed. Dilutional hyponatremia has been noted 
with chlorpropamide, and very occasionally with tol-
butamide. In contradistinction, tolazamide and 
acetohexamide appear to have a proximal tubular 
diuretic effect. 
Side effects of phenformin consist primarily of 
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gastrointestinal reactions. Lactic acidosis, however, is 
a serious problem, particularly in the phenformin-
treated diabetic with liver or renal disease, who is 
vulnerable to a variety of medical conditions which 
may lead to tissue hypoxia, that is, myocardial in-
farction, peripheral vascular disease with gangrene, 
and gastrointestinal bleeding. In addition, alcohol 
and phenformin are a particularly dangerous combi-
nation. 
There are a number of drugs which may interact 
and potentiate the effects of the sulfonylurea com-
pounds. These include phenylbutazorie, probenecid, 
alcohol, salicylates, and monamine oxidase inhib-
itors. The list is growing, and the clinician treating 
the diabetic with sulfonylureas must be constantly on 
the alert. 
The indications for oral agent therapy are rela-
tive, depending upon the patient's age, weight, fasting 
and postprandial blood sugar levels, and intensity of 
symptoms. Oral agents have a place in the manage-
ment of the maturity onset diabetic. The aim of ther-
apy of the diabetic patient is to produce normal 
weight for frame and height, to obtain as close to 
normal fasting and postprandial blood glucose levels 
as possible, to maintain normal lipid levels, and to 
keep the patient free from hypoglycemic episodes. 
Diet or insulin therapy or both are the bases of treat-
ment for the non-obese patient with fasting blood 
glucose values above 160 mg/ JOO ml. A weight reduc-
tion regimen, however, is the mainstay of management 
of the obese maturity onset diabetic. This requires 
constant dietary counseling by the physician, the 
dietician, and the nurse-educator. In most cases, if 
weight reduction is successful, plasma glucose and 
lipid levels will approach normal values, and the pa-
tient will usually become asymptomatic. If the plasma 
glucose still remains high, and particularly if the patient 
is still symptomatic, the sulfonylurea agents may be 
tried. If hyperglycemia is not controlled within a short 
period of time, by either short- or intermediate-acting 
agents, as well as long-acting sulfonylurea com-
pounds, then insulin should be administered; the 
"uncontrolled" patient may also have been taking 
other drugs during this period which may antagonize 
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the action of the oral agents, for example, corticoste-
roids in pharmacologic doses, excessive doses of thy-
roid hormones, diuretics which may produce moder-
ate to severe hypokalemia, oral contraceptives, and 
nicotinic acid in pharmacologic doses. More signifi-
cantly, the patient must be warned against increasing 
weight gain during the administration of these oral 
agents. All these factors must be borne in mind in the 
consideration of "secondary failures ." Hypoglycemia 
during oral therapy may result from overdosage (that 
is, failure to titrate dosage downward), poor choice 
of the oral therapeutic agent, omission of meals, renal 
or hepatic insufficiency, and interaction with other 
drugs, or alcohol. 
In conclusion, comment is made on the findings 
of the University Group Diabetes Program (UGDP). 
The purpose of the UGDP was to determine whether 
or not control of blood glucose levels would help to 
prevent or delay vascular disease in non-insulin-re-
quiring diabetics. After 81/2 years of follow-up at 12 
university-affiliated treatment centers, "The findings 
of the study indicate that the combination of diet and 
tolbutamide therapy is no more effective than diet 
alone in prolonging life. Moreover, the findings sug-
gest that tolbutamide and diet may be less effective 
than diet alone or diet and insulin, at least insofar as 
cardiovascular mortality is concerned." The debate 
on the validity of this study still rages . A number of 
the criticisms leveled against the study by diabetolog-
ists, other clinicians, epidemiologists, and statisti-
cians are discussed. These include inappropriate pa-
tient selection and randomization, higher risk factors 
at the outset of the study, manipulation of elec-
trocardiographic data, risk factors such as smoking 
and hypertension not measured or monitored, use of 
fixed dosage of drug, clinic preponderance regarding 
mortality (it has been alleged that the bulk of tolbuta-
mide mortality occurred in four clinics, Birmingham, 
Boston, Cincinnati, and Minneapolis), use of "pa-
tient data" against "computerized data," neglect of 
appropriate "vascular" history, neglect of "co-mor-
bidity," contradictory clinical studies here and 
abroad, and the danger of extrapolation of the 
UGDP findings to other sulfonylurea agents. 
